Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) has been assigned an average rating of “Buy” from the ten brokerages that are currently covering the stock, Marketbeat.com reports. Ten equities research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have issued a report on the stock […]
Pliant Therapeutics (NASDAQ:PLRX – Free Report) had its target price reduced by Royal Bank of Canada from $53.00 to $50.00 in a research report report published on Wednesday morning, Benzinga reports. Royal Bank of Canada currently has an outperform rating on the stock. PLRX has been the subject of a number of other research reports. […]
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $48.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 190.56% from the stock’s previous close. Several […]
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $48.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 190.56% from the stock’s previous close. Several […]
Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) have earned a consensus recommendation of “Buy” from the eleven brokerages that are covering the stock, MarketBeat Ratings reports. Eleven analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have issued a report on the stock in […]